Lexaria Bioscience Corporation (LEXX) ニュース

LEXX was unsuccessful with CBD because it wasn't clinically tested and approved for a particular medical affliction. The idea with the oral Liraglutide and/ or CBD for Hypertension is the drugs, after testing and approval, would be the only oral drugs of their kinds in the world and could be subscribed by doctors for whatever they are approved to treat. i.e. hypertension, weight loss, T2 diabetes amongst many other afflictions being discovered all the time! IMO It's definitely a good side bet for them.
https://lexariabioscience.com/2025/02/20/lexarias-strategic-business-pursuit-of-dehydratech-liraglutide/

Granted new mgmt...but I feel like you might be right. I would like to see it, but seems like an empty threat simply because they could have already had their own products (NSAIDs, ED drugs) if they really wanted to be a manufacturer/producer. If they were serious, and wanted to make products, they would have jumped at knocking off existing drugs when the FDA approved their tech as not altering the carrier drug. Plus, historically, ViPova tea, TurboCBD, Chrgd...not exactly successful products. Their primary goal is still licensing. Maybe the idea of a competing at a product level speeds up an offer?

The line about developing their own products -- not too sure about that https://lexariabioscience.com/2025/02/27/the-global-revolution-in-healthcare-driven-by-glp-1-drugs-and-the-role-of-lexaria-bioscience/

https://mailchi.mp/99c620a576e3/ethics-board-approval-received-for-dehydratech-tirzepatide-glp-1-study-arm?e=aa4bd7bcad

My guess is more dilution, high R&D expenses by Dr John for rat studies on multiple fronts ( good but big pharma is not. impressed by binders filled with various rat studies) and mgt salaries just for Bunka, Dr John and the new CEO at about a million a year plus perks. A miracle if I get my money back. IMHO GLTA

Can someone explain to me why this is dropping like a rock?

U:LEXX Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Pursuing the world’s first-ever orally-dosed liraglutide

Kelowna, British Columbia – February 20, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has made a strategic business decision to further investigate the commercial opportunities and applications for a unique new GLP-1 solution: orally taken liraglutide processed with our wholly-owned DehydraTECH™ enhancement technology.

“Our ability to work with liraglutide, which went off-patent last year, is an opportunity that does not often present itself,” said Rich Christopher, CEO of Lexaria. “Lexaria has already demonstrated that our unique DehydraTECH technology seems to deliver potent oral delivery performance characteristics to liraglutide. This opens the door to the possibility of Lexaria developing and selling the world’s first oral capsule or tablet version of liraglutide.”

As part of that strategic business decision, Lexaria has already filed certain patent applications related to DehydraTECH-enhanced oral liraglutide which, if granted, will further support Lexaria’s ability to commercialize oral DehydraTECH-liraglutide. Presently, there is no oral version of liraglutide available commercially anywhere in the world and Lexaria is hopeful that potential new patent awards in this sector could be of strategic value to the Company.

Lexaria’s patent applications are reinforced by the successful animal study results announced on November 20, 2024 that evidenced superior pharmacodynamic (“PD”) performance. In that study, DehydraTECH-liraglutide outperformed the Rybelsus® control group by week 12 both in terms of blood sugar and body weight control, by 11.53% (p

LEXX under $2

The only way Teddy gets interviews is by writing what the MGT wants...

It is known every time this dick head releases his report, the price goes down by 10-15. Both the Chris have been using him to dilute

Why I think Lexaria Bioscience deserves a market cap many times higher…………………..…………p 7
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_35ed41ca581a44afa5feb3df3fe46379.pdf

https://lexariabioscience.com/2025/02/11/lexaria-granted-two-new-dehydratech-patents-for-treatment-of-epilepsy/

More patents: https://lexariabioscience.com/2025/02/11/lexaria-granted-two-new-dehydratech-patents-for-treatment-of-epilepsy/

https://mailchi.mp/lexariabioscience.com/lexaria-biodistribution-study-for-dehydratech-glp-1-is-underway?e=aa4bd7bcad

https://mailchi.mp/lexariabioscience.com/lexaria-updates-its-ongoing-human-study-glp-1-h24-4?e=aa4bd7bcad

CEO LETER ; THINGS A RE GREAT! https://lexariabioscience.com/2025/01/30/lexaria-releases-annual-letter-from-the-ceo-3/

S-3 Filed with SEC This prospectus is part of a registration statement on Form S-3 that we filed with the Securities and Exchange Commission, or the SEC, using a "shelf” registration or continuous offering process. Under this shelf registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings up to a total aggregate offering price of $50,000,000.
FORM S-3
REGISTRATION STATEMENT. https://s3.amazonaws.com/sec.irpass.cc/2978/0001640334-25-000146.htm

https://www.theguardian.com/society/2025/jan/20/weight-loss-jabs-linked-to-reduced-risk-of-42-conditions-including-dementia

I wish they would add before/after muscle mass measurements to their Diabetes and Weight Loss testing parameters.

I would also be interested to see if they can somehow get involved in testing their GLP-1 pill to help treat addiction:

https://pennstatehealthnews.org/2024/04/qa-can-weight-loss-drugs-help-in-addiction-treatment/

Lexaria's January Presentation
https://d2ghdaxqb194v2.cloudfront.net/2978/195874.pdf

https://mailchi.mp/lexariabioscience.com/lexarias-human-glp-1-study-5-receives-independent-review-board-approval?e=aa4bd7bcad

Did they diluted this morning? Volume was around 2 million already early morning.

Just the salaries for Bunka, Dr J and Christopher are close to One million/yr plus perks and stock... thus one reason for a another raise...like these three need one.

Dr J has been on a do everything expedition for R & D as though $ is free - of course to him it is. Has filled a lot of binders but that is all.

It would be easy to accept if it is for FDA phase 1b IND studies.

Yeah, that was disappointing. I’m hoping it’s just early traders getting scared, but I don’t know.

My guess is another raise

Thought the exact same. Not sure why it dropped but typically with news the company dilutes. I assume this is the reason today?

This looks like a very good report. Oral treatment would be incredible. Half the adverse effects, and moving forward to study it more.

Looks ripe for a rebound

https://lexariabioscience.com/2025/01/14/lexarias-oral-dehydratech-tirzepatide-reduces-side-effects-by-half-with-comparable-efficacy-versus-eli-lillys-injectable-glp-1-gip-drug-zepbound/

10 Q IS OUT: https://s3.amazonaws.com/sec.irpass.cc/2978/0001640334-25-000058.htm

New SEC filing -- Take a look at Bunka's holdings that he "Earned???" https://s3.amazonaws.com/sec.irpass.cc/2978/0001348362-25-000001.htm. Maybe something good will come out the shareholders meeting.

Interesting that Dr J had a clause put into his compensation should control of the company change...and today more shares for insiders

MORE for mgt--https://s3.amazonaws.com/sec.irpass.cc/2978/0001640334-25-000018.htm

As of the moment MGT has made gains for themselves..,

well taken care of. kind of a pisser to reward before the big gains. like these guys don't make enough already. then we hear the excuses they must be rewarded to attract and keep them on board.

DR John getting taken care of:: SEC FILING --https://s3.amazonaws.com/sec.irpass.cc/2978/0001640334-25-000009.htm. GLTA

https://scitechdaily.com/one-step-closer-to-a-cure-breakthrough-harmine-pill-sparks-hope-for-500-million-diabetics-worldwide/

Special Report: Positive interview with new Lexaria CEO Richard Christopher………….………..…..p 5
https://4495825a-d729-4d8f-ade8-e78f828e1c8d.usrfiles.com/ugd/449582_489f4449167841c7a10795654a27a169.pdf

https://scitechdaily.com/a-new-way-to-treat-obesity-scientists-discover-brain-molecules-that-control-food-cravings/?fbclid=IwY2xjawHVSg5leHRuA2FlbQIxMQABHaWu6OvEsm4A_GJOyL9J0nqeoXv4bteRR64L7x3FVatGhARa91bxwVw80g_aem_gHScQVBUijW8Po92ag6LWQ

Big milestone!! First ever Lexaria clinical study has begun! Great news.

https://mailchi.mp/lexariabioscience.com/lexarias-registered-glp-1-study-4-begins-dosing?e=aa4bd7bcad

8K OUT: https://s3.amazonaws.com/sec.irpass.cc/2978/0001640334-24-001908.htm

https://mailchi.mp/lexariabioscience.com/lexaria-forms-new-scientific-advisory-board?e=aa4bd7bcad

Will Dr. Gibson and Oxford University be involved in the Hypertension trial?
https://www.bidmc.org/research/research-by-department/medicine/cardiovascular-medicine/academic-research-organizations

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dr. Gibson joining Lexaria's new scientific advisor board

KELOWNA, BC / ACCESSWIRE / December 17, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the appointment of Dr. Michael Gibson as its new Chief Medical Advisor. Dr. Gibson will collaborate directly with President John Docherty as Lexaria's patented DehydraTECH drug delivery platform continues to expand its applications in GLP-1 and hypertension.

C. Michael Gibson M.S., M.D., is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. Gibson founded PERFUSE in 1987 which served as the TIMI Data coordinating center that coordinated data for the first 50 TIMI trials. The Baim institute was formerly known as Harvard Clinical Research Institute and was founded in 2000.

The combined institutes have led over 1,250 studies, published 5,500 manuscripts in peer review literature (including 144 in the New England Journal of Medicine) and have led 70 FDA submissions from their network of 7,000 sites in 57 countries worldwide. Since 2014, Gibson has consistently been ranked as one of the world's most highly cited authors in all of science by Thomson Reuters. In 2021, he was named one of the Fifty of the Most Influential Voices in Healthcare by Medika Life. His work has been cited over 170,000 times.

"Lexaria's drug delivery technology offers exciting new pathways towards improving pharmacokinetic drug performance that could unlock a new era of reduced drug waste and adverse side effects combined with enhanced efficacy," said Dr. Gibson. "I'm excited to pursue new and improved applications for this exciting technology."

"Dr. Gibson has a wealth of knowledge and experience that will benefit Lexaria, particularly in the area of hypertension which remains an area of intense interest for Lexaria," said John Docherty, President. "On behalf of everyone at Lexaria, I welcome Dr. Gibson's contributions as our new Chief Medial Advisor and member of our scientific advisory board."

As Chief Medical Advisor, Dr. Gibson will participate with other scientific and medical experts within Lexaria's newly-formed scientific advisory board in pursuing Lexaria's prioritized objectives in the fields of drug delivery optimization.

Dr. Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 34,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices such as one that alarms to alert a patient to heart attack. He founded WikiDoc.org and WikiPatient.org and is Editor-In-Chief of over 2,200 active contributors who have edited the content of over 100,000 chapters millions of times over the past 15 years. Gibson also founded www.clinicaltrialresults.org. Gibson serves as Chief Medical Correspondent for the American College of Cardiology. Gibson has over 435,000 followers on social media where he is a leading influencer, second only to Sanjay Gupta in some polls

About Lexaria Bioscience Corp. & DehydraTECH

DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many patents pending worldwide. For more information, please visit www.lexariabioscience.com.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

INVESTOR CONTACT:

George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202

SOURCE: Lexaria Bioscience Corp.

SEC FILING TODAY: https://s3.amazonaws.com/sec.irpass.cc/2978/0001640334-24-001893.htm#a7

Epidiolex(CBD) to be tested for psychosis in clinical trial.
https://www.nature.com/articles/s41591-024-03383-y.epdf?sharing_token=NFA7NDYtTS0ZRsTRHT7ZutRgN0jAjWel9jnR3ZoTv0MVhSv3wC-EELnLsdOkhOVURlkhM34-KkFvGlRWpPdfpsS3QQdX0H5r4ZoGmv7Dyum8hWvkAaFm33y3VChjQwRY0mBbjbpBksYL9CnwoagXDkJmMcuQvsrZp6MtrE2uCFE%3D

https://mailchi.mp/lexariabioscience.com/liraglutide-processed-with-dehydratech-to-be-studied-in-human-glp-1-study-5?e=aa4bd7bcad